Safety and Tolerability of Recombinant Humanized Anti-PD-1 Monoclonal Antibody for Patients With Advanced Breast Cancer
Clinical trial NCT02838823 · COMPLETED
Trial details
- NCT number
- NCT02838823
- Sponsor
- Shanghai Junshi Bioscience Co., Ltd.
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2016-07-01
- Primary completion
- 2018-12-01
- Enrollment
- 20
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.